FDA GMLP Principles

FDA/Health Canada/MHRA Good Machine Learning Practice Guiding Principles
United States · FDA/HC/MHRA GMLP Guiding Principles (Oct. 27, 2021)

Status
In effect
Took effect
October 27, 2021
Applies to
Manufacturers of ML medical devices
Enforced by
FDA / CDRH (via existing FDCA authorities)

Joint guiding principles by FDA, Health Canada, and the UK MHRA on safe development of ML-enabled medical devices. Updated by FDA's 2024 Transparency Guiding Principles.

Who is protected: Patients whose care involves ML medical devices

Legal detail

10 GMLP guiding principles cover good software engineering, representative datasets, independence of training/test data, model-design tailored to data and clinical use, focus on the performance of the human-AI team, clinically meaningful test performance, training data quality, transparency, monitoring of deployed performance, and clear cybersecurity practices.

Key facts

JurisdictionUnited States
LevelFederal
StrengthModerate
EnactedOctober 27, 2021
CitationFDA/HC/MHRA GMLP Guiding Principles (Oct. 27, 2021)
Private right of actionNo, agency enforcement only
PenaltiesFDCA enforcement
Topicshealthcare AI · automated decision-making
Agency pageGood Machine Learning Practice for Medical Device Development — FDA

More AI rules in United States

Related healthcare AI rules elsewhere

See something wrong or out of date? Submit a correction. Every entry must carry a verifiable source.